Fig 2: Individual assessment of NRGPI genes and association with necroptosis. (A) Spearman’s correlation between NRGPI genes and infiltration of macrophages in the TCGA STAD dataset assessed with TIMER database. (B) Spearman’s correlation between NRGPI genes and KEGG TGF-ß signaling pathway signature genes and (C) WNT signaling pathway signature genes. (D) mRNA expression level of RIPK1, RIPK3, MLKL (necroptosis core mediators), NRGPI oncogenes (SERPINE1, GPX3, GRP, FCN1, CYTL1, CNTN1, PLCL1, and APOD), and markers of WNT signaling pathway (WNT2B, WNT9A) and TGF- signaling pathway (TGFB1, TGFB3) in gastric cancer cells (AGS and MNK45) after being treated with a combination of human recombinant TNF-a, SMAC mimetic, and zVAD-FMK (TSZ) to induce necroptosis or added necroptosis inhibitor (necrostatin-1) to inhibit necroptosis. Graph shows mean ± SD. *P<0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not signficant.

Fig 3: Representative images of expression (brown, cell cytoplasmic/nucleus stain) of RIPK1, RIPK3, MLKL (necroptosis core mediators), NRGPI oncogenes (SERPINE1, GPX3, GRP, FCN1, CYTL1, CNTN1, PLCL1, and APOD), markers of WNT signaling pathway (WNT2B, WNT9A), TGF-ß signaling pathway (TGFB1, TGFB3), and macrophage (CD63, CD206, CD163) in the clinical samples of stomach adenocarcinoma.